The Food and Drug Administration has recently approved the first new medication for Alzheimer’s disease in nearly twenty years.
There is controversy surrounding the decision made by the FDA.
Some Alzheimer’s experts have argued that there was not enough evidence to indicate that the drug can help patients.
The drug aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms.
The drug will be marketed under the brand name Aduhelm.
It is the first approved treatment to attack the disease process of Alzheimer’s instead of just addressing dementia symptoms.
According to Biogen, the list price would be $56,000 a year.
Additionally, the cost to patients could also increase significantly when factors such as the costs for diagnostic testing and brain imaging are considered.
About six million people in the United States and roughly 30 million globally have Alzheimer’s, a number expected to double by 2050.
Currently, five medications approved in the United States can delay cognitive decline for several months in various Alzheimer’s stages.
The U.S. Food and Drug Administration (FDA) said there was “substantial evidence that aducanumab reduces amyloid beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients.”
Readers Bureau, Contributor
Edited by Jesus Chan
Do you want to add feedback to this story?
Please add a comment in the box below or send an email to firstname.lastname@example.org, send us a message on WhatsApp at 646-874-7976 or Call us at 201-500-7715